News
from the fight to #SaveIndiePharmacy
New York Times’ The Middlemen series
Too Rare to Matter? How Insurers Fail Millions with ‘Uncommon’ Diseases.
When you’re healthy, you might see insurance as a tedious but dependable safety net. For rare disease patients, the truth is harsher: we wish inconvenience was the worst of it.
Drugmakers including Purdue Pharma paid pharmacy benefit managers not to restrict painkiller prescriptions, a New York Times investigation found.